{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', '10.4.2.2. Safety Analyses', '69', '10.4.3.', 'Multiplicity Strategy', '70', '10.4.4.', 'Covariates and Subgroups of Interest', '70', '10.4.5.', 'Interim Analyses', '71', '10.4.6.', 'Analysis of Patient-Reported Outcomes Measures and', 'Actigraphy', '72', '11. REFERENCES', '73', '12. APPENDICES', '74', '12.1.', 'Appendix 1: Abbreviations and Trademarks', '74', '12.2.', 'Appendix 2: Study Governance Considerations', '77', '12.2.1.', 'Regulatory and Ethical Considerations', '77', '12.2.2.', 'Financial Disclosure', '78', '12.2.3.', 'Informed Consent Process', '78', '12.2.4.', 'Data Protection', '78', '12.2.5.', 'Quality Control (Study Monitoring)', '78', '12.2.6.', 'Data Quality Assurance', '79', '12.2.7.', 'Source Documents', '80', '12.2.8.', 'Study and Site Closure', '80', '12.2.9.', 'Records Retention', '80', '12.2.10.', 'Dissemination of Clinical Study Data', '81', '12.2.11.', 'Publication Policy', '81', '12.2.12.', 'Clinical Events Committee', '82', '12.2.13. Safety Review Team (SRT)', '82', '12.3. Appendix 3: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '83', '12.3.1.', 'Definition of Serious Adverse Events', '85', '12.3.2.', 'Recording of AEs and SAEs', '86', '12.3.3.', 'Evaluating AEs and SAEs', '87', '12.4.', 'Appendix 4: Female Eligibility Criteria, Contraceptive Guidance and', 'Collection of Pregnancy Information', '89', '12.5.', 'Appendix 5: Genetics', '92', '12.6.', 'Appendix 6: Liver Safety: Required Actions and Follow-up', 'Assessments', '95', '12.7. Appendix 7: Country Specific Requirements', '98', '12.7.1. French Administrative Considerations and Specifics', 'Requirements', '98', '12.8.', 'Appendix 8: Stratification by Region-Region Groupings', '102', '12.9.', 'Appendix 9: Protocol Amendment History', '103', '9']['2016N298481_02', 'CONFIDENTIAL', '205270', '1.', 'SYNOPSIS', 'Protocol Title: A 28-week, randomized, double-blind, placebo-controlled, parallel-', 'group, multi-center, study in rhEPO na\u00efve non-dialysis participants with anemia', 'associated with chronic kidney disease to evaluate the efficacy, safety and effects on', 'quality of life of daprodustat compared to placebo.', 'Short Title: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat in', 'Non-Dialysis participants evaluating Hemoglobin and Quality of life (ASCEND-NHQ)', 'Rationale:', 'Daprodustat (GSK1278863) is a hypoxia-inducible factor prolyl hydroxylase inhibitor', '(HIF-PHI) currently being investigated as a treatment for anemia associated with chronic', 'kidney disease (CKD) in both dialysis and non-dialysis participants.', 'Blood hemoglobin (Hgb) concentration, transferrin saturation and ferritin levels are the', 'primary markers for evaluation of anemia in CKD patients. Initially, non-dialysis CKD', 'patients receive iron therapy, to ensure that sufficient iron is available for erythropoiesis', 'prior to initiating therapy with recombinant human erythropoietin (rhEPO) for anemia. A', 'one to three month trial of oral iron is generally recommended in rhEPO na\u00efve patients', 'with non-dialysis CKD. However, if poor compliance is seen with oral iron therapy due', 'to lack of efficacy or gastrointestinal intolerance, IV iron may be administered in patients', 'requiring iron repletion. rhEPO therapy is generally initiated in non-dialysis CKD', 'patients once Hgb has dropped below 10 g/dL at which stage benefits outweigh the risks', 'associated with this therapy. Thus, the question arises whether initiation of treatment with', 'a PHI, such as daprodustat, in the rhEPO na\u00efve and iron sufficient population might result', 'in Hgb benefits that are reflected as benefits in symptoms and quality of life.', 'This Phase 3 double blind study will be conducted to assess efficacy, safety and effects', 'on quality-of-life of daprodustat compared to placebo. Study participants will be rhEPO', 'na\u00efve and had limited IV iron exposure at baseline. The purpose of this study is to', 'evaluate the effect of daprodustat, on hemoglobin response and quality of life, compared', 'to placebo over 28 weeks. The primary endpoint is Hgb superiority of daprodustat versus', 'placebo, and a principal secondary endpoint includes measures of health related quality-', 'of-life.', '10']\n\n###\n\n", "completion": "END"}